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Abstract 
In this case report we detail the difficult case of a 74-year-old male patient who was 
transferred to our cardiac intensive care unit in severe shock with an acute abdomen. His 
abdomen was emergently explored revealing isolated gastric necrosis and ischemia. A 
subtotal gastrectomy was performed and the patient was discharged from the hospital 
34 days after surgery. Postoperatively we learned that for the preceding 2 weeks the 
patient had doubled the dose of Forcalide syrup which he had been taking for his 
reactive airway disease for many years. Formal testing of this fluid revealed a 
concentrated sugar-based solution with a high concentration of both Ephedra and 
potassium chloride. Final pathology of the resected stomach demonstrated patent 
vessels to the stomach with extensive microvascular thrombosis and full-thickness 
gastric necrosis. On final summation of this case we concluded that the Ephedra in the 
patient’s Forcalide syrup caused the microvascular necrosis seen in the stomach and 
should be added to the list of potential adverse reactions seen with the ingestion of 
ephedrine. 
 
Case Report 
A 74-year-old male presented unconscious to a small community hospital in florid shock. Following 
prompt intubation and initial hemodynamic stabilization the patient was transferred to our cardiac 
intensive care unit for a presumed devastating cardiac event. On arrival the patient was found to be in 
extremis with his initial objective presentation listed in table 1. A history was obtained from the 
patient’s wife who stated that the patient was in his usual state of health until two weeks prior when his 
reactive airway disease began to worsen with the progression of winter. 
For the past 67 years the patient had been taking Karo syrup with ephedrine (Forcalide syrup) every 
day to treat his reactive airway disease. The patient had carried the diagnosis of reactive airway disease 
following the accidental ingestion of gasoline at age 7. Since that time his local pharmacist has prepared 
the Karol-Ephedrine syrup, which the patient later described had ‘always’ successfully treated the 
symptoms of his airway disease. When the patient’s symptoms began to worsen two weeks prior to his 
admission, he doubled his daily intake of the Karol-Ephedrine syrup. During the first week his  
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respiratory system improved and the patient was able to return to his usual daily activities. However, 
during the second week, one week prior to admission, he began experiencing a dull epigastric pain that 
progressed to periodic bouts of extreme pain. The patient’s pain was associated with fever and anorexia, 
however, he continued to consume the double dose of Karol-Ephedrine syrup. On the morning of 
presentation the patient’s wife found him disoriented, febrile, and experiencing constant extreme 
abdominal pain. 
After initial evaluation by our cardiac critical care colleagues, the diagnosis of septic shock was made 
with suspicion of an abdominal source. On our initial evaluation he was intubated, sedated but not 
chemically paralyzed. His abdomen was rigid and markedly distended. His wife reported progression of 
the severe episodes of epigastric pain. A STAT portable chest and abdominal radiograph demonstrated a 
massively dilated stomach with decompressed loops of small bowel (fig. 1). A nasogastric tube was 
placed, which immediately released a rush of air and 200 ml of blood-stained bilious fluid. 
The patient was emergently taken to the operating room for exploratory laparotomy. Upon initial 
abdominal exploration, more than 3 liters of transudative ascites was evacuated which revealed the 
obvious cause of the patient’s sepsis and acute abdomen. The stomach was decompressed due to the 
placement of a nasograstic tube preoperatively, but showed extensive necrosis extending along the 
greater curvature and dependent portion of the body of the stomach (fig. 2). Close inspection of the 
stomach revealed multiple microperforations along the greater curvature where the necrosis was most 
severe. Interestingly, palpable pulses were present in the vessels supplying the greater curvature of the 
stomach and there was no evidence of visceral vascular occlusive disease. With the extent of gastric 
insult a subtotal gastrectomy was required and his intestinal continuity was restored with a Roux-en-Y 
cardiojejunostomy. The patient tolerated the procedure well and was successfully discharged from the 
hospital. He discontinued his use of the Karol-Ephedrine syrup and did not have complications 
associated with gastrointestinal ischemia anymore. 
Postoperatively we investigated the cause of the patient’s unusual isolated gastric ischemia. Along 
with a more extensive history, as detailed above, we obtained a sample of the patient’s Karol-Ephedrine 
syrup and tested the liquid along with the patient’s serum for the presence of illegal substances and the 
presence of ephedrine (table 2). The sample of the syrup was submitted for gas chromatography/mass 
spectrometry (GC/MS) screening. A 2.0 ml sample of the Karol-Ephedrine syrup was combined with 
100 μl of an internal standard solution (0.2 mg/ml benzocaine and 0.2 mg/ml cyheptamide), acidified 
with 1 ml buffer (pH 4.0) and extracted into 6 ml ethyl acetate/chloroform (20:80 v/v). Extracts were 
dried under 30°C nitrogen and reconstituted in 100 μl of pyridine/hexane (10:90). Using an Agilent 
5973/6890 GC/MS, 1 μl of reconstituted sample was injected onto a DB-5MS column and subjected to 
gas chromatographic separation. Drugs present were identified by chromatographic retention time 
compared against a mixture of drug standards, and by structural analysis provided by mass 
spectrometry [1]. Of the tested substances known to cause vasoconstriction or gastric mucosal injury, 
ephedrine was the only substance that was found to be present in the patient’s Karol-Ephedrine syrup 
and his serum. Hematoxylin and eosin staining of the gastrectomy specimen demonstrated the presence 
of chronic gastritis, microvascular thrombosis with full thickness necrosis, and multiple gastric 
perforations. 
Discussion 
Ephedra is an alkaloid chemical compound obtained from the Ephedra sinica plant [2]. 
In traditional Chinese medicine this plant has been used for millennia to treat disorders 
such as asthma, upper respiratory illnesses and seasonal allergies [3]. In recent years 
Ephedra has gained tremendous popularity as a diet drug because of its biochemical 
activity as a stimulant and a prothermogenic agent [2, 4]. The stimulant activity of 
Ephedra suppresses appetite while the prothermogenic property increases the body’s 
metabolism, all leading to improved weight loss [5]. However, over the past decade a 
number of well-documented reports of ischemic stroke and adverse cardiac events linked 
to Ephedra have lead to a FDA ban of the drug in April 2004 as a dietary supplement 
[2, 4, 6–12]. 
Ephedra causes a number of physiologic effects in addition to suppressing appetite and 
increasing metabolism [2, 3, 5, 12]. Ephedra causes an increase in blood pressure, heart  
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rate and bronchial dilation [4, 7, 8, 11–13]. The effect of Ephedra on the vasculature is 
also well documented and comes from the drugs ability to function as a vasoconstrictor 
[8, 12, 13]. This effect as a potent vasoconstrictor has lead to the above listed cardiac and 
cerebral blood flow complications. However, to date no study or case report has shown 
Ephedra to cause microvascular thrombosis and intestinal necrosis. 
The literature contains relatively few examples of isolated gastric ischemia from 
chemical sources. Ethanol, aspirin and other vasoactive compounds have been implicated 
in inducing isolated microvascular ischemia in the stomach [14–18]. Ethanol is thought to 
induce gastric ischemia by stimulating the release of endothelin-1, which is a potent 
vasoconstrictor [16–18]. Aspirin has been shown to reduce local blood flow, leading to 
microvascular ischemia and gastric mucosal injury [14, 15, 19, 20]. 
We conclude that the Ephedra in the patient’s Forcalide syrup lead to severe 
vascoconstriction with resultant microvascular thrombosis and gastric necrosis. Since this 
case the physicians and the pharmacy have discontinued prescribing or dispensing 
Forcalide syrup. This is the first case report implicating Ephedra as the cause of 
gastrointestinal ischemia and gastric perforation. We strongly recommend that this albeit 
rare scenario be added as a warning to the list of potential adverse reactions seen with the 
ingestion of Ephedrine. 
 
 
 
Table 1. Initial vitals, labs and hemodynamic values at initial presentation to the surgical team 
Initial data at presentation  Values 
Heart rate, beats/min 
Systolic blood pressure, mm Hg 
Diastolic blood pressure, mm Hg 
Temperature, °C 
Central venous pressure, mm Hg 
Pulmonary capillary wedge pressure, mm Hg 
Systemic vascular resistance (dynes•sec/cm
5) 
Cardiac index, l/min/BSA 
Hemoglobobin, g/dl 
Leukocytes (×10
9/l) 
Platelets (×10
9/l) 
Lactate, mmol/l 
103 
155 
69 
35.1 
12 
21 
1,457 
1.83 
10.6 (ref. 13.5–17.5) 
15.4 (ref. 3.5–10.5) 
254 (ref. 150–450) 
3.9 (ref. 0.6–2.3) 
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Table 2. Test results of the patient’s Karol-Ephedrine syrup and serum 
Results  Substances  
screened  Karol-Ephedrine syrup  serum 
Caffeine 
Cocaine 
Ephedrine 
Ethanol 
Ibuprofen 
Indomethacin 
Ketoprofen 
Ketorolac 
Lidocaine 
Salicylate 
negative 
negative 
positive 
negative 
negative 
negative 
negative 
negative 
negative 
negative 
negative 
negative 
positive 
negative 
negative 
negative 
negative 
negative 
negative 
negative 
 
 
Fig. 1. Preoperative abdominal radiograph demonstrated a massively dilated stomach with otherwise 
normal bowel gas pattern. 
 
 
 
Fig. 2. Intraoperative photograph. The ischemia and necrosis is isolated to the stomach with multiple 
microperforations noted along the greater curvature. 
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